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Abstract
Background: Initial management of chemotherapy-induced febrile neutropaenia (FN) comprises empirical therapy
with a broad-spectrum antimicrobial. Currently, there is sufficient evidence to indicate which antibiotic regimen
should be administered initially. However, no randomized trial has evaluated whether adherence to an antimicrobial
stewardship program (ASP) results in lower rates of mortality in this setting. The present study sought to assess the
association between adherence to an ASP and mortality among hospitalised cancer patients with FN.
Methods: We conducted a prospective cohort study in a single tertiary hospital from October 2009 to August 2011.
All adult patients who were admitted to the haematology ward with cancer and FN were followed up for 28 days.
ASP adherence to the initial antimicrobial prescription was determined. The mortality rates of patients who were
treated with antibiotics according to the ASP protocol were compared with those of patients treated with other
antibiotic regimens. The multivariate Cox proportional hazards model and propensity score were used to estimate
28-day mortality risk.
Results: A total of 307 FN episodes in 169 subjects were evaluated. The rate of adherence to the ASP was 53%. In a
Cox regression analysis, adjusted for propensity scores and other potential confounding factors, ASP adherence was
independently associated with lower mortality (hazard ratio, 0.36; 95% confidence interval, 0.14–0.92).
Conclusions: Antimicrobial selection is important for the initial management of patients with FN, and adherence to
the ASP, which calls for the rational use of antibiotics, was associated with lower mortality rates in this setting.
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Background
Febrile neutropaenia (FN), secondary to cytotoxic chemo-
therapy, is a medical emergency that requires the immediate
administration of empirical broad-spectrum antimicrobials
to prevent the characteristic high levels of morbidity and
mortality [1,2]. The signs and symptoms of infection are
often subtle or absent because of the lack of an appropriate
inflammatory response [3], which underscores the import-
ance of early assessment and management of patients with
this syndrome. Patients should be treated initially with
empiric intravenous therapy, comprising β-lactam anti-
biotic monotherapy with antipseudomonal activity (i.e.,
ceftazidime, cefepime, piperacillin/tazobactam, merope-
nem or imipenem) [4]. The addition of a second class
of antimicrobial to the initial regimen is indicated in spe-
cial situations, such as the addition of vancomycin in cases
of haemodynamic instability, suspected catheter-related
infection, pneumonia, or infection of the skin and soft
tissue, or the inclusion of metronidazole in cases with
gastrointestinal symptoms (e.g., diarrhoea, abdominal pain
and perianal pain) [4,5].
The implementation of an antimicrobial stewardship
program (ASP) aims to prevent or slow the emergence of
multidrug-resistant (MDR) pathogens, reduce the costs
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related to healthcare and decrease morbidity and mortality
[6,7]. Currently, there is a growing interest in the stringent
enforcement of ASPs in the context of FN, given the ex-
tensive emergence in cancer patients of antimicrobial-
resistant strains that are associated with increased risk of
morbidity, mortality and cost [8].
Although various studies have demonstrated improve-
ments in clinical outcomes with ASPs (e.g., higher cure
rates, lower rates of treatment failure and a lower inci-
dence of infections caused by resistant germs) [9-15],
few studies have examined the impact of an ASP on
mortality [16]. The available evidence on the effective-
ness of ASPs in reducing mortality in FN is scarce [17],
and any data originated from studies that were not pri-
marily designed for the determination of this outcome.
Thus, the aim of this cohort study was to evaluate the
association between adherence to an ASP and mortality
among hospitalised cancer patients with FN.
Methods
Study design, setting and patients
A prospective cohort study was conducted in the
haematology ward of the Hospital de Clínicas de Porto
Alegre, Rio Grande do Sul, a teaching hospital and ter-
tiary referral centre for bone marrow transplantation in
southern Brazil. In this hospital, the application of an
ASP protocol for FN (which is based on the guidelines
of the Infectious Diseases Society of America [18]) has
been part of the institutional recommendations since
2003. We screened all consecutive cancer patients ad-
mitted between October 2009 and August 2011. Patients
aged ≥ 18 years with neutropaenia (absolute neutrophil
count < 500 cells/mm3 or < 1,000 cells/mm3 with an ex-
pectation of decreasing to < 500 cells/mm3 during the
following 48 h) and fever (a single axillary temperature
measurement ≥ 38.5°C or body temperature ≥ 38.0°C sus-
tained over a 1-h period) were eligible for this study. We
excluded subjects who were receiving non-curative cancer
treatment, had an indication for outpatient treatment, had
a history of allergies to any antibiotics recommended by the
ASP of the institution or had neutropaenia with a specific
aetiology other than an adverse reaction to chemotherapy.
Study groups
The main independent variable of the present study was
adherence to the hospital’s ASP guidelines [19], which was
measured by determining whether the recommended anti-
microbial therapy was administered as soon as the symp-
toms of FN matched those in the ASP guidelines
(Figure 1). ASP adherence was determined by a medical
research team not associated with patient care at the time
of first antibiotic prescribing for a patient with FN. The
following situations were classified as non-adherence to
the ASP: administration of any antibiotic that was not
advised by the ASP; prescription of metronidazole, vanco-
mycin or clindamycin that was not approved by the ASP;
and the absence of cefepime in any circumstance, of
metronidazole in subjects with diarrhoea or perineal pain,
of clindamycin in patients with a suspected oral cavity in-
fection, or of vancomycin during hypotension, suspected
catheter-related infection or cutaneous manifestations of
infection.
Covariate definitions
All baseline characteristics were verified at the onset of
fever by a medical research team not associated with pa-
tient care. The Multinational Association for Supportive
Care in Cancer (MASCC) risk index score [20] was ap-
plied to determine the risk of serious complications dur-
ing FN; episodes were classified as high risk if the score
was < 21 points and as low risk if the score was ≥ 21
points. Clinical comorbidity was defined as the presence
of heart failure, diabetes mellitus, chronic pulmonary
disease, chronic liver disease or chronic renal failure.
The patients were divided into two groups based on
their chemotherapy regimens: a high-dose chemotherapy
group that included patients who underwent haemato-
poietic stem cell transplantation or induction chemo-
therapy, and a standard-dose chemotherapy group that
included patients who underwent consolidation or main-
tenance chemotherapy. Hypotension was characterised
by systolic blood pressure < 90 mmHg. A suspected
source of infection in the oral cavity was determined by
the presence of a septic tooth or abscess in the mouth.
Cutaneous manifestations of infection were defined by
the presence of skin signs of inflammation (heat, redness
or swelling). A suspected catheter-related infection was
defined by the presence of any phlogistic sign at the cen-
tral venous catheter insertion site. Diarrhoea was charac-
terised by the presence of loose or watery stool.
Microbiological studies were performed at the onset of
fever according to practice standards, and included two
separate blood samples from two different sites. In the
absence of an indwelling central venous catheter, the
two blood sets were obtained from two distinct periph-
eral veins. When an indwelling central venous catheter
was present, one sample for blood culture was obtained
through the indwelling central venous catheter, and the
other was collected from a peripheral vein. Bacteraemia
by coagulase-negative Staphylococcus spp. was defined
as two positive results from two independent cultures.
Bacteraemia in one positive culture was considered diag-
nostic for other microorganisms. Polymicrobial blood-
stream infection (BSI) was characterised as a bacteraemic
episode caused by at least two different pathogens isolated
from the same blood sample. The susceptibilities of the
isolated pathogens to antibiotics were evaluated according
to the recommendations of the Clinical and Laboratory
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Standards Institute [21]. Multidrug resistant (MDR) bac-
teraemia was defined as a BSI with methicillin-resistant
staphylococci or vancomycin-resistant enterococci for
Gram-positive bacteria or as resistance to three or more
classes of antimicrobial agents for Gram-negative bacteria.
Outcome and follow-up
The primary outcome of the study was mortality 28 days
after the onset of FN. Patients were followed up through
interviews and medical record reviews using a standar-
dised case report form by researchers who were not asso-
ciated with the attending physician’s team. Follow-up was
maintained for 28 days after the onset of fever in FN pa-
tients. For patients who were discharged before 28 days,
follow-up phone calls were made on the 28th day after the
onset of FN to determine whether they were still alive; if a
patient was deceased at the time of the phone call, the sur-
vival time was calculated based on the date of death re-
ported by the family. A second episode of FN in the same
patient was considered only if the patient remained free of
signs or symptoms of infection for at least 7 days after the
completion of the treatment for the first episode and if all
causative organisms were eradicated.
Statistical analysis
Observational studies are often limited by an imbalance
in both known and unknown confounders, which make
some FN patients more likely to receive antimicrobial
treatment according to ASP guidelines than to receive
other antimicrobial treatments. Therefore, we applied a
propensity score adjustment to balance baseline charac-
teristics and to reduce the probability of treatment selec-
tion bias. The propensity score (probability of receiving
an antibiotic recommended by the ASP) was calculated
using a stepwise multivariate logistic regression model,
in which the dependent variable was treatment accord-
ing to ASP guideline; all variables that were considered
to potentially influence antimicrobial prescribing and
that had a P value < 0.20 in a univariate analysis were in-
cluded. In the multivariate model, independent variables
were eliminated from the highest to the lowest P value
but remained in the model if the P value was < 0.05
(backward method). The validity of the model was
assessed by estimating the area under the receiver oper-
ating characteristics (ROC) curve using c-statistics. The
balance in the covariates across the study groups was
demonstrated by testing for differences in individual co-
variates between the ASP group and non-ASP group
after stratifying by quintiles of propensity scores. The
multivariate Cox proportional hazard model adjusted by
propensity score was used to assess the association of
ASP adherence with 28-day mortality, and all covariates
with a P-value < 0.15 in a univariate analysis were in-
cluded. In the multivariate model, independent variables
Figure 1 Initial antimicrobial selection for the in-patient treatment of FN according to the ASP of the Hospital de Clínicas de Porto Alegre.
*High-risk patients = MASCC score < 21 points; Low-risk patients = MASCC score ≥ 21 points. Low-risk patients were treated with intravenous
antibiotics if they had one or more of the following: presence of clinical comorbidities, FN after high-dose chemotherapy, expectation of
duration of neutropenia > 7 days, documented infection, clinical instability (e.g. hypotension, acute respiratory failure, acute renal failure) and
gastrointestinal intolerance (e.g. severe mucositis, vomiting). ASP, antimicrobial stewardship program; FN, febrile neutropaenia; MASCC,
Multinational Association for Supportive Care in Cancer.
Rosa et al. BMC Infectious Diseases 2014, 14:286 Page 3 of 8
http://www.biomedcentral.com/1471-2334/14/286
were eliminated according to backward selection but
remained in the model if the P-value was < 0.05. The
hazard ratios (HRs) were estimated along with the 95%
confidence intervals (CIs). Propensity score weighted
Kaplan–Meier curves were used to calculate the time-
dependent occurrence of death; the log-rank test was
used for comparisons between groups. The software
used for the statistical analysis was STATA version 12
(StataCorp LP, TX, USA).
Ethical issues
Written, informed consent was obtained from all study
participants. The institutional review board of the Hos-
pital de Clínicas de Porto Alegre approved the study.
Results
Study population
In total, twenty cases (11 in the ASP group and 9 in the
non-ASP group) met criteria for exclusion from the co-
hort. The reasons for exclusion were indication for out-
patient treatment (9 cases in the ASP group and 7 cases
in the non-ASP group), non-curative cancer treatment
(1 case in the ASP group and 1 case in the non-ASP
group), history of allergies to any antibiotics recommended
by the ASP (1 case in the non-ASP group) and aeti-
ology of FN other than an adverse reaction to chemo-
therapy (1 case in the ASP group). Overall, 307
episodes of FN (in 169 patients) were evaluated during
the study period. Of these, 81% occurred after 48 h of
hospitalisation (250 cases). Seventy-one subjects (42%
of the study population) had two or more episodes of
FN, and the maximum number of episodes studied per
patient was four. Antibiotic prophylaxis with fluoroqui-
nolones was not administered to any patient. There
were no losses to follow-up. The overall rate of adher-
ence to the ASP of this institution was 53% (162 cases).
The mortality of this cohort was 9.4% (29 patients), al-
though no deaths occurred during the follow-up pe-
riods of two or more FN episodes in the same patient.
The baseline clinical characteristics of all episodes of
FN evaluated in the present cohort are shown in Table 1.
As a result of the non-randomized design, the baseline
characteristics of patients with FN receiving antimicro-
bial therapy recommended by the ASP were different
from those of patients receiving antimicrobial therapy
non-adherent to the ASP. These differences were particu-
larly important regarding the presence of clinical comor-
bidity; history of antibiotic use in the previous 30 days;
Table 1 Comparison of baseline variables between FN cases receiving antimicrobial therapy recommended by the ASP
and those receiving other antimicrobial regimens (non-ASP)
Variables ASP group N = 162 Non-ASP group N = 145 PS adjusted, P-value
Age, mean ± SD, years 41.8 ± 14.5 39.4 ± 13.8 0.07
Female sex (%) 80 (49.4) 68 (46.9) 0.76
Clinical comorbidity (%) 33 (20.4) 43 (29.6) 0.31
Type of neoplastic disease 0.71
- Haematological (%) 128 (79.0) 114 (78.6)
- Solid tumour (%) 34 (21.0) 31 (21.4)
Chemotherapy regimens 0.95
- High-dose (%) 88 (54.3) 76 (52.4)
- Standard-dose (%) 74 (45.7) 69 (47.6)
Relapsing underlying disease status (%) 77 (47.5) 78 (53.8) 0.30
Antibiotic use in the previous 30 days (%) 49 (30.2) 61 (42.0) 0.15
Hospitalisation in the previous 30 days (%) 59 (36.4) 61 (42.0) 0.59
Median ANC at the time of diagnosis of FN (IQR), cells/mm3 175 (60–340) 100 (40–260) 0.61
ANC < 100 cells/mm3 at the time of FN (%) 62 (38.3) 68 (46.9) 0.78
Nosocomial-acquired FN (%) 127 (78.4) 123 (84.8) 0.83
Hypotension at the time of diagnosis of FN (%) 4 (2.5) 27 (18.6) 0.46
Diarrhoea at the time of diagnosis of FN (%) 14 (8.6) 48 (33.1) 0.10
Perianal pain at the time of diagnosis of FN (%) 6 (3.7) 26 (17.9) 0.67
Suspected source of oral cavity infections (%) 3 (1.8) 12 (8.3) 0.85
Cutaneous manifestations of infection (%) 8 (5.0) 42 (28.9) 0.92
High-risk MASCC score (%) 35 (21.6) 48 (33.1) 0.95
Note. P-values are provided for the differences between the two groups after propensity score adjustment.
PS, propensity score; SD, standard deviation; ANC, absolute neutrophil count; IQR, interquartile range (P25–P75).
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proportion of FN episodes with high-risk MASCC scores;
and hypotension, diarrhoea, perianal pain and cutaneous
manifestations of infection at the time of diagnosis of
FN. However, after weighting by the propensity score,
all differences decreased to non-significant values, which
suggested that propensity score matching adjusted appro-
priately for the initial treatment selection bias (Table 1).
The microbiological characteristics of all FN cases with
documented BSI are shown in Table 2. During the study
period, 115 BSIs were diagnosed. The predominant blood
isolates were Escherichia coli (42%), coagulase-negative
staphylococci (31%), Klebsiella pneumonia (11%), Pseudo-
monas aeruginosa (9%), viridans streptococci (7%) and
Enterococcus spp. (3%). Among all BSIs evaluated, 38 epi-
sodes (33%) were caused by MDR bacteria; of these, 68%
were caused by Gram-positive bacteria, 29% were caused
by Gram-negative bacteria, and 3% were caused by both
Gram-positive and Gram-negative bacteria.
The proportion of FN episodes with time to initial
antibiotic administration > 1 h was 25.3% in the ASP
group and 24.8% in the non-ASP group. The overall
in vitro sensitivity rate of blood isolates to the initial
antibiotic regime administered was 88% in the ASP
group and 86% in the non-ASP group. No case was eli-
gible for oral treatment at the onset of FN, mainly due
to the high prevalence of clinical comorbidities, FN after
high-dose chemotherapy and expectation of duration of
neutropenia > 7 days among cases stratified as low risk
by MASCC score. Additionally, no case with an incor-
rect antibiotic dose was documented in the cohort.
Antimicrobial regimens prescribed with no adherence to
the ASP
Antimicrobial monotherapy was more frequently pre-
scribed to FN patients when there was no adherence to the
ASP (Table 3). Among the monotherapies, cefepime was
the most commonly prescribed, followed by piperacillin/
tazobactam. In cases prescribed combination therapy, the
most frequently used were cefepime +metronidazole and
cefepime + vancomycin. In cases of non-adherence to the
ASP, the prescribed antimicrobial spectrum was considered
overtreatment in 11% of cases (16 episodes), and insuffi-
cient in 89% (129 episodes) according ASP guideline. In
the insufficient therapy group, there were indications
for the use of vancomycin, metronidazole, clindamycin
and cefepime in 56% (73 episodes), 51% (66 episodes), 5%
(7 episodes) and 2% (3 episodes) of cases, respectively.
Predictors of initial antimicrobial prescribing according to
the ASP
We found several clinical factors that were significantly
associated with antibiotic treatment according to ASP
recommendations (Table 4). Older patients were more
likely to be treated according to the ASP. Conversely,
hypotension, diarrhoea, perianal pain and cutaneous
manifestations of infection at the time of diagnosis of
FN, and the presence of a comorbidity were more fre-
quently found in cases with treatment non-adherent to
ASP guidelines. The propensity score model showed an
excellent discriminatory ability (area under the ROC
Table 2 Microbiological characteristics of FN cases
Variables ASP group Non-ASP group
N = 162 N = 145
Documented BSI (%) 57 (35.2) 58 (40.0)
Blood isolates
- Escherichia coli (%) 20 (12.3) 24 (16.5)
- Coagulase-negative staphylococci (%) 16 (9.9) 20 (13.7)
- Klebsiella pneumonia (%) 6 (3.7) 7 (4.8)
- Pseudomonas aeruginosa (%) 6 (3.7) 5 (3.4)
- Viridans strepcococci (%) 6 (3.7) 2 (1.3)
- Enterococcus spp. (%) 2 (1.2) 2 (1.3)
- Serratia spp. (%) 1 (0.6) 1 (0.7)
- Enterobacter spp. (%) 2 (1.2) 0 (0)
- Candida spp. (%) 0 (0) 2 (1.3)
- Salmonella spp. (%) 1 (0.6) 0 (0)
- Staphylococcus aureus (%) 0 (0) 1 (0.7)
- Kocuria varians (%) 1 (0.6) 0 (0)
BSI involving Gram-positive MDR bacteria 12 (7.4) 15 (10.3)
BSI involving Gram-negative MDR bacteria 9 (5.5) 3 (2.0)
Note: There were 12 cases of polymicrobial BSI (5 in the ASP group and 7 in
the non-ASP group).
BSI, bloodstream infection; MDR, multidrug resistant.
Table 3 Antimicrobial regimens prescribed to 145 non-ASP
cases
Antibiotic scheme Number (%)
Monotherapy 129 (89.0)
- Cefepime 95 (65.6)
- Piperacillin/tazobactam 26 (17.9)
- Imipenem/meropenem 7 (4.8)
- Ciprofloxacin 1 (0.7)
Combination therapy 16 (11.0)
- Cefepime +metronidazole 5 (3.4)
- Cefepime + vancomycin 3 (2.0)
- Cefepime + amikacin 1 (0.7)
- Cefepime + azithromycin 1 (0.7)
- Cefepime + vancomycin + ampicillin 1 (0.7)
- Piperacillin/tazobactam + vancomycin 3 (2.1)
- Cefuroxime + azithromycin 1 (0.7)
- Vancomycin +metronidazole 1 (0.7)
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curve = 89%). Microbiological characteristics were not
entered into the propensity score modeling because its
results were unknown at the baseline.
Mortality
The 28-day mortality rate was significantly lower in pa-
tients who were treated according to the ASP recommen-
dations compared with the non-ASP group (log-rank
P = 0.02) (Figure 2).
In the univariate Cox proportional hazards model, 28-day
mortality during FN (Table 5) was associated with non-
adherence to the ASP recommendations (P = 0.001), relaps-
ing disease stages (P = 0.001), a confirmed BSI (P = 0.001), a
high-risk MASCC score (P < 0.001), hypotension at the
time of diagnosis of FN (P < 0.001) and time to anti-
biotic therapy > 1 h (P = 0.001). After the propensity
score-weighted multivariate analysis (Table 6), the
variables that constituted independent predictors for
mortality included presentation with relapsing disease
stages (P = 0.003), a confirmed BSI (P = 0.003), a high-
risk MASCC score (P = 0.008), and time to antibiotic
therapy > 1 h (P = 0.001). Adherence to the ASP was
independently associated with a higher survival rate
(P = 0.03). Mortality was attributable to infection in all
29 patients who died.
Discussion
The present study showed that, after risk adjustment, hos-
pitalised FN cases treated according to ASP recommenda-
tions had a relative risk reduction in 28-day mortality of
64% compared with cases receiving antimicrobial treat-
ment non-adherent to ASP recommendations.
Our findings reinforce the relevance of appropriate ad-
herence to ASPs, and the importance of the continued
evaluation of these programs for the medical commu-
nity. ASPs are often based on the best-available evidence,
with consideration of local data on antimicrobial resist-
ance, and primarily seek to reduce morbidity and mor-
tality in patients for whom the protocols were designed.
Additionally, ASPs are often focused on implementing
strategies that prioritize the rational use of antimicro-
bials to reduce the incidence of antibiotic-resistant bac-
teria. This is of paramount importance in the current
scenario of bacterial multidrug resistance associated with
low availability of effective antibiotics to treat these
infections.
Previous studies have shown rates of mortality and ad-
herence to an ASP similar to those found in our cohort.
For example, Kuderer et al. reported in-hospital mortal-
ity of 9.5% in subjects with FN [22], and compliance to
an ASP was found in 56% of FN cases in a study by Jin
et al. [23]. The impact of ASP implementation on clin-
ical outcomes in different infectious diseases [24,25]
serves as a theoretical basis for the hypothesis that ASP
reduces mortality.
The relatively low adherence to the ASP found in our
study indicates the need for strategies to increase med-
ical adherence to ASPs. We hypothesise that noncompli-
ance with the ASP in our study is related to prescribing
practices of multi-tasking attending physicians, who do
not take time to consult the institutional ASP protocol.
In the present study, most FN cases non-adherent to the
ASP were treated with monotherapy even though there
was a high prevalence of specific factors that indicated the
need for changes in the initial antibiotic regimen (i.e., diar-
rhoea, perianal pain, hypotension, cutaneous manifest-
ation of infection, and suspected oral cavity infection).
Moreover, the prescribed antimicrobial spectrum was clas-
sified as insufficient in most cases in the non-ASP group.
The present study had some limitations. Antimicrobial
modifications during the course of FN were not
Table 4 Multivarate logistic model of baseline factors





Age, years 1.03 1.007–1.06 0.01
Clinical comorbidity 0.40 0.18–0.89 0.02
Hypotension at the time of diagnosis of FN 0.04 0.01–0.15 <0.001
Diarrhoea at the time of diagnosis of FN 0.05 0.02–0.11 <0.001
Perianal pain at the time of diagnosis of FN 0.07 0.02–0.21 <0.001
Suspected source of oral cavity infections 0.05 0.01–0.22 <0.001
Cutaneous manifestations of infection 0.04 0.01–0.11 <0.001
Note: Variables entered into the model: age, clinical comorbidity, ANC at the
time of the diagnosis of FN, nosocomial-acquired FN, antibiotic use in the
previous 30 days, high-risk MASCC score, hypotension at the time of diagnosis
of FN, diarrhoea at the time of diagnosis of FN, perianal pain at the time of
diagnosis of FN, suspected source of oral cavity infections, and cutaneous
manifestations of infection.
CI, confidence interval.
Figure 2 Kaplan–Meier curves of 28-day mortality according
adherence to ASP after propensity score weighting.
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examined. Furthermore, the study was susceptible to
biases inherent to observational studies (selection, as-
sessment and confounding); however, the possibility of
systematic errors was minimised by the proper measure-
ment of variables and outcomes with previously defined
objective criteria, the use of standardised data collection
and follow-up performed by a research team that was
not involved in patient care, and also the application of
propensity scores, which allowed the balancing of im-
portant covariates in the two study arms.
Conclusion
This study found that adherence to the ASP was associ-
ated with lower mortality. Additional studies are re-
quired to assess the impact of ASP adherence on
mortality for different nosocomial infections. The inves-
tigation of factors leading to non-adherence by pre-
scribers should also be thoroughly explored to develop
new approaches to increase the adherence to ASPs.
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Table 5 Prognostic factors of 28-day mortality in FN patients by Cox regression univariate analysis
Variables Mortality group Survival group HR (95% CI) P-value
N = 29 N = 278
Age, mean ± SD, years 41.6 ± 15.0 40.6 ± 14.1 1.00 (0.98–1.03) 0.62
Clinical comorbidity (%) 6 (20.6) 70 (25.1) 0.82 (0.33–2.01) 0.66
Type of neoplastic disease 24 (82.8) 218 (78.4) 1.20 (0.45–3.15) 0.70
- Haematological (%) 5 (17.2) 60 (21.6) – –
- Solid tumour (%)
Relapsing underlying disease status (%) 23 (79.3) 132 (47.4) 4.30 (1.75–10.58) 0.001
Chemotherapy regimens 9 (31.0) 155 (55.8) 0.39 (0.17–0.86) 0.02
- High-dose (%) 20 (69.0) 123 (44.2) – -
- Standard-dose (%)
Median ANC at the time of the diagnosis of FN (IQR), cells/mm3 130 (40–300) 130 (50–310) 1.00 (0.99–1.00) 0.37
ANC < 100 cells/mm3 at the time of the diagnosis of FN 16 (55.1) 114 (41.0) 1.68 (0.80–3.49) 0.16
Duration of neutropaenia, median (IQR), days 8 (4–20) 9 (6–17) 0.97 (0.93–1.01) 0.23
Documented BSI (%) 20 (69.0) 95 (34.2) 3.91 (1.78–8.60) 0.001
BSI involving Gram-positive MDR bacteria (%) 2 (6.9) 25 (9.0) 0.74 (0.17–3.12) 0.68
BSI involving Gram-negative MDR bacteria (%) 3 (10.3) 9 (3.2) 2.70 (0.81–8.94) 0.10
High-risk MASCC score (%) 18 (62.1) 65 (23.4) 5.03 (2.37–10.65) <0.001
Hypotension at the time of diagnosis of FN (%) 9 (31.0) 22 (7.9) 4.72 (2.14–10.37) <0.001
Time to antibiotic therapy >1 h 15 (51.7) 62 (22.3) 4.13 (1.85–9.20) 0.001
In vitro sensitivity of blood isolates to initial antibiotic treatment administered (%) 22 (75.8) 246 (88.4) 0.47 (0.20–1.10) 0.08
ASP adherence (%) 6 (20.7) 156 (56.1) 0.21 (0.08–0.53) 0.001
HR, hazard ratio; SD, standard deviation; IQR, interquartile range (P25–P75); BSI, bloodstream infection; MDR, multidrug resistant.
Table 6 Prognostic factors of 28-day mortality in FN
patients by Cox regression multivariate analysis adjusted
using a propensity score
Variable HR (95% CI) P-value
Relapsing underlying disease status 4.43 (1.65–11.86) 0.003
Documented BSI 3.78 (1.55–9.20) 0.003
High-risk MASCC score 3.01 (1.33–6.83) 0.008
Time to antibiotic >1 h 3.85 (1.71–8.62) 0.001
ASP adherence 0.36 (0.14–0.92) 0.03
Note: Variables entered into the model: propensity score, ASP adherence, time
to antibiotic >1 h, in vitro sensitivity of blood isolates to initial antibiotic
treatment administered, high-risk MASCC score, documented BSI, BSI involving
Gram-negative MDR bacteria, relapsing underlying disease status, hypotension
at the time of diagnosis of FN, and high-dose chemotherapy regimens.
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